Evidence map›Paper›PMID 26038827›Full record

SynthesisPloS one2015

Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis.

Sheng-Ming Deng, Wei Zhang, Bin Zhang, Yin-Yin Chen, Ji-Hui Li, Yi-Wei Wu

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 5 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 5 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Standardized Uptake Values Derived fromContrast media & molecular imaging · 2018
    Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Application ofDiagnostics (Basel, Switzerland) · 2025
    Article
  10. Article
  11. Review
  12. Non-[Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  13. Article
  14. Article
  15. Review
  16. Preclinical evaluation of [European journal of nuclear medicine and molecular imaging · 2022
    Article
  17. Predictive Value ofDiagnostics (Basel, Switzerland) · 2022
    Article
  18. Article
  19. Article
  20. Prognostic Prediction of BRCA Mutations byMolecular imaging and radionuclide therapy · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sheng-Ming DengDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China; School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, China.
Wei ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Bin ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China; Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China.
Yin-Yin ChenDepartment of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Ji-Hui LiDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yi-Wei WuDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
First Affiliated Hospital of Soochow University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo study the correlation between 18F-FDG uptake and cell proliferation in cancer patients by meta-analysis of published articles.

methodsWe searched PubMed (MEDLINE included), EMBASE, and Cochrane Database of Systematic Review, and selected research articles on the relationship between 18F-FDG uptake and Ki-67 expression (published between August 1, 1994-August 1, 2014), according to the literature inclusion and exclusion criteria. The publishing language was limited to English. The quality of included articles was evaluated according to the Quality Assessment of Diagnosis Accuracy Studies-2 (QUADAS-2). The correlation coefficient (r) was extracted from the included articles and processed by Fisher's r-to-z transformation. The combined correlation coefficient (r) and the 95% confidence interval (CI) were calculated with STATA 11.0 software under a random-effects model. Begg's test was used to analyze the existence of publication bias and draw funnel plot, and the sources of heterogeneity were explored by sensitivity and subgroup analyses.

resultsAccording to the inclusion and exclusion criteria, 79 articles were finally included, including 81 studies involving a total of 3242 patients. All the studies had a combined r of 0.44 (95% CI, 0.41-0.46), but with a significant heterogeneity (I2 = 80.9%, P<0.01). Subgroup analysis for different tumor types indicated that most subgroups showed a reduced heterogeneity. Malignant melanoma (n = 1) had the minimum correlation coefficient (-0.22) between 18F-FDG uptake and Ki-67 expression, while the thymic epithelial tumors (TETs; n = 2) showed the maximum correlation coefficient of 0.81. The analytical results confirmed that correlation between 18F-FDG uptake and Ki-67 expression was extremely significant in TETs, significant in gastrointestinal stromal tumors (GISTs), moderate in patients with lung, breast, bone and soft tissue, pancreatic, oral, thoracic, and uterine and ovarian cancers, average in brain, esophageal and colorectal cancers, and poor in head and neck, thyroid, gastric and malignant melanoma tumors. Subgroup analysis indicated that positron emission tomography (PET) or PET/CT imaging technology or Ki-67 and standardized uptake value (SUV) measurement technology did not significantly affect the results of r values, and Begg's test showed no significant publication bias.

conclusionIn cancer patients, 18F-FDG uptake showed a moderate positive correlation with tumor cell proliferation. Different tumor types exhibited varied degree of correlation, and the correlation was significant in TETs and GSTs. However, our results need further validation by clinical trials with a large sample of different tumor types.

Indexed as

Biological TransportBiomarkers, TumorCell ProliferationFluorodeoxyglucose F18Gene ExpressionHumansKi-67 AntigenNeoplasmsOrgan SpecificityPositron-Emission TomographyRadiopharmaceuticalsRegression AnalysisTomography, X-Ray ComputedTumor Cells, CulturedBiomarkers, TumorFluorodeoxyglucose F18Ki-67 AntigenRadiopharmaceuticals

Identifiers

PMID26038827
PMCPMC4454667
OpenAlexW1520095978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.